Aurobindo Pharma Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 9, 2026
- Posted by: Harsh Piplani
- Category: Results
Aurobindo Pharma share price Rs 1,679.90 on 9 September 2026, down 0.72%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 1,032.00 crore. Q2 FY26 base a profit of Rs 848.00 crore.
Quick Answer
The Aurobindo Pharma Q2 results date for FY27 is not confirmed, and Aurobindo Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 8,286.00 crore in revenue and a profit of Rs 848.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Aurobindo Pharma Q2 results FY27 announcement is the next scheduled earnings event for Aurobindo Pharma Ltd., a large generic drug maker manufacturing and exporting formulations and active pharmaceutical ingredients, with the United States as its biggest market. The stock traded at Rs 1,679.90 on the NSE on 9 September 2026, down 0.72% from the previous close of Rs 1,692.00, about 2.2% below its 52-week high of Rs 1,717.00 and 62.2% above its 52-week low of Rs 1,035.40.
What makes the Aurobindo Pharma Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 8,286.00 crore of revenue and a profit of Rs 848.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 9,150.00 crore and a profit of Rs 1,032.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Aurobindo Pharma Q2 Results FY27 Date?
The Aurobindo Pharma Q2 results date for FY27 is not confirmed. As of 9 September 2026, Aurobindo Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Aurobindo Pharma Q2 results date becomes public through that filing rather than through any advance announcement.
The Aurobindo Pharma Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Aurobindo Pharma.
Aurobindo Pharma Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Aurobindo Pharma Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Aurobindo Pharma. The Aurobindo Pharma Q2 results watchlist below is built from what the company has actually reported and disclosed.
The first is the consistency. Revenue rose in every one of the last five quarters from Rs 7,868 crore to Rs 9,150 crore, and profit from Rs 824 crore to Rs 1,032 crore, with the operating margin held in a 20% to 21% band throughout.
The second is the September 2025 base of Rs 8,286 crore in revenue, a 20% operating margin and Rs 848 crore of profit. Revenue has since grown about 10%, so the comparison should be comfortable if the margin holds.
The third is that the Q1 FY27 profit step up was partly non-operating. Other income reached Rs 224 crore against a Rs 107 crore to Rs 123 crore run rate, so roughly Rs 100 crore of the Rs 111 crore increase sits in that line.
Check Aurobindo Pharma Ltd. Live Fundamentals on the Univest Screener
Aurobindo Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Aurobindo Pharma Ltd. reported revenue of Rs 9,150.00 crore in Q1 FY27, up 16.29% from Rs 7,868.00 crore in Q1 FY26, and a profit of Rs 1,032.00 crore at the net level, up 25.24% from Rs 824.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was up 3.35% over the March 2026 quarter figure of Rs 8,853.00 crore, and net profit was up 12.05% from Rs 921.00 crore in Q4 FY26. Operating margin stood at 21% in Q1 FY27 against 20% in the September 2025 quarter, which is the comparison the Aurobindo Pharma Q2 results print will be read against.
Q2 FY26 Base: The Comparison Aurobindo Pharma Q2 Results FY27 Must Beat
Aurobindo Pharma Ltd. reported revenue of Rs 8,286.00 crore and a profit of Rs 848.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Aurobindo Pharma Q2 results preview.
Net profit in that base quarter was below the Rs 1,032.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 8,286.00 crore sits below the Rs 9,150.00 crore of the June 2026 quarter, which frames how much sequential movement the Aurobindo Pharma Q2 results print needs to show growth.
Aurobindo Pharma Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 8,286.00 | 848.00 |
| Q3 FY26 (Dec 2025) | 8,646.00 | 910.00 |
| Q4 FY26 (Mar 2026) | 8,853.00 | 921.00 |
| Q1 FY27 (Jun 2026) | 9,150.00 | 1,032.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Aurobindo Pharma Q2 results preview uses.
Revenue across those four quarters ranged from Rs 8,286.00 crore to Rs 9,150.00 crore, and net profit from Rs 848.00 crore to Rs 1,032.00 crore. That spread is the honest context for the Aurobindo Pharma Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Aurobindo Pharma Q2 Results FY27
The Aurobindo Pharma Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Aurobindo Pharma has already reported.
United States Generic Pricing
Price erosion on established products runs against new approvals and launches, and the net of the two sets export revenue. That balance is what the results commentary should quantify.
Regulatory Inspections and Plant Status
Manufacturing sites supplying regulated markets are subject to periodic inspection, and an adverse observation can restrict supply from a facility. Plant status disclosed with results carries more forward information than the quarter’s revenue.
Clean Record at a Moderate Multiple
Tax rates held between 29% and 34% in every quarter, no exceptional item appears, and profit sits below pre-tax profit throughout. The stock trades at a price-to-earnings ratio of 25.61 on a return on equity of 10.10%.
Aurobindo Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print
Aurobindo Pharma share price today is Rs 1,679.90 on the NSE, down Rs 12.10 or 0.72% from the previous close of Rs 1,692.00 on 9 September 2026, ahead of the Aurobindo Pharma Q2 results announcement.
| Metric | Value (9 September 2026) |
|---|---|
| NSE Symbol | AUROPHARMA |
| Current Market Price | Rs 1,679.90 |
| 52-Week High | Rs 1,717.00 |
| 52-Week Low | Rs 1,035.40 |
| Market Capitalisation | Rs 96,775 crore |
| PE Ratio | 25.61 |
| PB Ratio | 2.58 |
| EPS (TTM) | Rs 65.60 |
| Book Value per Share | Rs 652.00 |
| Debt to Equity | 0.21 |
| Return on Equity | 10.10% |
| 50-Day Moving Average | Rs 1,605.27 |
| 200-Day Moving Average | Rs 1,378.31 |
| RSI (14) | 62.59 |
The stock trades above both its 50-day average of Rs 1,605.27 and its 200-day average of Rs 1,378.31, with a 14-day RSI of 62.59. None of this is a view on where the shares go once the Aurobindo Pharma Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Aurobindo Pharma Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Aurobindo Pharma Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Aurobindo Pharma Q2 results print in proportion.
- Revenue against the Rs 8,286.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 848.00 crore in that same quarter
- Operating margin against 21% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Aurobindo Pharma Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Aurobindo Pharma Q2 Results FY27
The Aurobindo Pharma Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Aurobindo Pharma Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Aurobindo Pharma Q2 results FY27 print faces a base of Rs 8,286.00 crore in revenue and a profit of Rs 848.00 crore, with the most recent quarter having delivered Rs 9,150.00 crore and a profit of Rs 1,032.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Aurobindo Pharma, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Aurobindo Pharma Q2 Results FY27
What is the Aurobindo Pharma Q2 results date for FY27?
Ans. The Aurobindo Pharma Q2 results date for FY27 is not confirmed. Aurobindo Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Aurobindo Pharma Q2 results 2026 cover?
Ans. The Aurobindo Pharma Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Aurobindo Pharma Ltd. reports revenue, operating profit and net profit for that period, and the Aurobindo Pharma Q2 results filing also carries the notes to the accounts.
What were the Aurobindo Pharma Q1 FY27 results?
Ans. Aurobindo Pharma Ltd. reported revenue of Rs 9,150.00 crore in Q1 FY27 and a profit of Rs 1,032.00 crore at the net level. Revenue was up 16.29% versus Q1 FY26 and net profit was up 25.24% from Rs 824.00 crore in Q1 FY26.
What were Aurobindo Pharma Q2 FY26 results in the September 2025 quarter?
Ans. Aurobindo Pharma Ltd. reported revenue of Rs 8,286.00 crore and a profit of Rs 848.00 crore in Q2 FY26. Operating margin was 20%. Those figures form the base for the Aurobindo Pharma Q2 results FY27 comparison.
What are the main Aurobindo Pharma Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Aurobindo Pharma Q2 results expectations centre on revenue against the Rs 8,286.00 crore base, net profit against a profit of Rs 848.00 crore, operating margin against 21% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Aurobindo Pharma share price today ahead of the Q2 earnings?
Ans. Aurobindo Pharma share price is Rs 1,679.90 on the NSE as of 9 September 2026, down 0.72% from Rs 1,692.00. The stock is about 2.2% below its 52-week high of Rs 1,717.00 and 62.2% above its 52-week low of Rs 1,035.40, at a market capitalisation of Rs 96,775 crore.
Is Aurobindo Pharma a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Aurobindo Pharma Ltd.. The stock trades at a price-to-book ratio of 2.58 with a return on equity of 10.10%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
